Abbott Receives FDA Approval for Prone MRI Scans With Neuromodulation Systems

Reuters01-26
Abbott Receives FDA Approval for Prone MRI Scans With Neuromodulation Systems

Abbott Laboratories has received U.S. Food and Drug Administration (FDA) approval for patients with its neuromodulation systems to undergo MRI scans in the prone position. This expanded approval applies to Abbott's chronic pain portfolio, including the Proclaim™ SCS family, Eterna™ SCS system, and the Proclaim™ DRG neurostimulation system, and is available to both new and existing patients. The approval enables broader access to diagnostic imaging for individuals living with chronic pain who use these systems.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbott Laboratories published the original content used to generate this news brief on January 23, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment